WO2006010041A3 - Morpholino antisense drugs for human herpesvirus 8 - Google Patents

Morpholino antisense drugs for human herpesvirus 8 Download PDF

Info

Publication number
WO2006010041A3
WO2006010041A3 PCT/US2005/024352 US2005024352W WO2006010041A3 WO 2006010041 A3 WO2006010041 A3 WO 2006010041A3 US 2005024352 W US2005024352 W US 2005024352W WO 2006010041 A3 WO2006010041 A3 WO 2006010041A3
Authority
WO
WIPO (PCT)
Prior art keywords
hhv8
human herpesvirus
morpholino antisense
antisense drugs
bind
Prior art date
Application number
PCT/US2005/024352
Other languages
French (fr)
Other versions
WO2006010041A2 (en
Inventor
Yan-Jin Zhang
David O Matson
Original Assignee
Eastern Virginia Med School
Yan-Jin Zhang
David O Matson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eastern Virginia Med School, Yan-Jin Zhang, David O Matson filed Critical Eastern Virginia Med School
Publication of WO2006010041A2 publication Critical patent/WO2006010041A2/en
Publication of WO2006010041A3 publication Critical patent/WO2006010041A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Abstract

The present invention provides antisense oligomers useful for the treatment or prevention of HHV8 viral infections. The antisense oligomers are directed to bind to a targeted HHV8 gene, which would inhibit the replication or tranformation of HHV8. The oligomers may bind to HHV8 genes, such as RTA, vIRF-1, v-Cyclin, LANA, vGCR, or vFLIP.
PCT/US2005/024352 2004-07-09 2005-07-08 Morpholino antisense drugs for human herpesvirus 8 WO2006010041A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58629104P 2004-07-09 2004-07-09
US60/586,291 2004-07-09

Publications (2)

Publication Number Publication Date
WO2006010041A2 WO2006010041A2 (en) 2006-01-26
WO2006010041A3 true WO2006010041A3 (en) 2007-06-21

Family

ID=35785762

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024352 WO2006010041A2 (en) 2004-07-09 2005-07-08 Morpholino antisense drugs for human herpesvirus 8

Country Status (1)

Country Link
WO (1) WO2006010041A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110224133A1 (en) * 2008-07-25 2011-09-15 University Of Southern California Highly Potent Peptides To Control Cancer And Neurodegenerative Diseases
CN102625852A (en) 2009-07-07 2012-08-01 南加利福尼亚大学 Biomarkers for the early detection of autoimmune diseases
WO2011032100A1 (en) * 2009-09-11 2011-03-17 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Inhibitors of kshv vil6 and human il6
US9687523B2 (en) 2010-02-04 2017-06-27 University Of Southern California Compositions and methods for the treatment of sjörgren's syndrome
US9606117B2 (en) 2011-01-13 2017-03-28 University Of Southern California Bioassay for the early detection of autoimmune diseases
WO2013019980A1 (en) 2011-08-03 2013-02-07 University Of Southern California Compositions and methods for the treatment of asthma and associated disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211468A1 (en) * 2000-07-31 2003-11-13 Yoshiyasu Aoki Specific binding agents for kshv vil-6 that neutralize a biological activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211468A1 (en) * 2000-07-31 2003-11-13 Yoshiyasu Aoki Specific binding agents for kshv vil-6 that neutralize a biological activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MASOOD ET AL.: "Human Herpesvirus-8-Transformed Endothelial Cells Have Functionally Activated Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor", AMERICAN JOURNAL OF PATHOLOGY, vol. 160, 2002, pages 23 - 29, XP003014078 *

Also Published As

Publication number Publication date
WO2006010041A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2007084667A3 (en) Fused heterobicyclic kinase inhibitors
WO2007042554A3 (en) Methods and compositions for treating immune disorders
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2007059257A8 (en) N4-phenyl-quinaz0line-4 -amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
WO2006133099A3 (en) Sirna microbicides for preventing and treating viral diseases
WO2008151304A8 (en) Selective inhibitors for cyclin-dependent kinases
WO2006128693A3 (en) 2 -oxo-i -pyrrolidine derivatives/ processes for preparing them and their therapeutic use on the central nervous system
WO2008115281A3 (en) Compounds for treating viral infections
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2007015866A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007064993A3 (en) Bicyclic protein kinase inhibitors
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2009133573A3 (en) A homeopathic formulation
WO2005046603A3 (en) Pyridine compounds
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2006010041A3 (en) Morpholino antisense drugs for human herpesvirus 8
WO2004009610A3 (en) Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases
WO2007015877A3 (en) Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2004094386A8 (en) Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
WO2007059125A3 (en) Hiv integrase inhibitors
WO2006124684A3 (en) Combination therapy comprising a taxane and a thymidylate synthase inhibitor
WO2005007141A3 (en) Ubiquitin ligase inhibitors and methods related thereto
WO2007028821A3 (en) Treatment of autoimmune diseases
WO2009116037A3 (en) NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase